Management of Highly Active Anti-retroviral Therapy-related Hyperlipidemia Among HIV-infected Patients in Taiwan

Completed

• Conditions: HIV

• Registration Number: NCT01697540
• Lead Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital

Brief Summary

1. Written informed consent must be obtained before any study specific procedures are undertaken.

2. The process of the experiment (brief describe) The patients must come back for follow during 4 to 12 weeks after starting the new therapy. The investigators will follow the patients' lipid profile and any side effects and stop the observation till 36 months after starting the new therapy. The serum level of HIV-VL, CD4, GOT, GPT, triglyceride, cholesterol, HDL-cholesterol, and LDL-cholesterol will be checked every 3 months. The patients' chart and all data will be delinked to protect the patients' right and privacy.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-09
• Study First Submitted: 2012-09-28
• Study First Submitted QC: 2012-10-01
• Study First Posted: 2012-10-02
• Status Verified: 2017-01
• Primary Completion: 2017-06-27
• Study Completion: 2017-06-27
• Last Update Submitted: 2018-08-08
• Last Update Posted: 2018-08-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• HIV-infected patients who receive HAART therapy but have metabolic side effects.
• Age over 20 years old

Read More

Exclusion Criteria

• Abnormal liver function: GOT or GPT 5 times over normal upper limit

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Tropical medicine center; 🇨🇳 Kaohsiung, Taiwan